Sign in

NCT04619888Completed

HeartLogic France Study: Heart Failure Patients Managed with the HeartLogic Algorithm

Follow-up of Heart Failure Patients with an Implantable Cardiac Defibrillator Enabled with the HeartLogic Algorithm - HeartLogic France Study

Source: ClinicalTrials.gov · Last updated 19 Nov 2024

Brief summary (registry, in English)

Heart Failure (HF) is a chronic disease that leads to numerous rehospitalisations and affects more than one million people in France. The main objective of this prospective multicentric French study is to describe the annual rate of unplanned hospitalisations for heart failure in a cohort of patients managed by a HeartLogic algorithm. Patients will be included if they fulfill the following requirements 1/Patient implanted with a cardiac defibrillator with or without resynchronisation with the HeartLogic index (RESONATE family, Boston Scientific); 2/History of heart failure (left ventricular ejection fraction ≤40 %; or at least one episode of clinical heart failure with elevated NT pro BNP≥450 ng/L). If a HeartLogic index ≥16 is noticed, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment.

Status (registry)
Completed
Study type
Observational
Enrollment
310 (actual)
First submitted
2 Nov 2020
Start date
10 Mar 2021
Primary completion date
30 Jul 2024
Lead sponsor
Poitiers University Hospital
NCT number
NCT04619888

What you commit to

  • Study type: Observational
  • Participants enrolled: 310
  • From 10 Mar 2021 to the primary completion date, 30 Jul 2024
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concomitant presence of a heart failure device other than cardiac resynchronisation such as a left ventricular assist device or a device for modulating cardiac contractility.

Other illness

  • Heart transplant project, or heart transplant patient
  • Refusal to take medication for heart failure
  • Patient with a mechanical heart valve

Other

  • Glomerular filtration rate \<30 ml/mn/m2 or dialysis,
  • Life expectancy ≤ 6 months
  • Remote monitoring of HeartLogic is not possible.

Who the study is looking for

  • Patient implanted with a cardiac defibrillator, with or without resynchronization, enabled with the HeartLogic index (RESONATE family, Boston Scientific)
  • History of heart failure (left ventricular ejection fraction ≤40 %; or at least one episode of clinical heart failure with elevated NT pro BNP≥450 ng/L)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
University Hospital of Brest
Coordinator of this site? Confirm its status
BrestFranceUnknown status
University hospital of Grenoble
Coordinator of this site? Confirm its status
GrenobleFranceUnknown status
Hospital of Lorient
Coordinator of this site? Confirm its status
LorientFranceUnknown status
University Hospital of Nantes
Coordinator of this site? Confirm its status
NantesFranceUnknown status
Clinique du Confluent
Coordinator of this site? Confirm its status
NantesFranceUnknown status
Hôpital Européen G Pompidou
Coordinator of this site? Confirm its status
ParisFranceUnknown status
Hopital La Salpétrière
Coordinator of this site? Confirm its status
ParisFranceUnknown status
University Hospital of Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceUnknown status
Clinique Pasteur
Coordinator of this site? Confirm its status
ToulouseFranceUnknown status
University Hospital of Tours
Coordinator of this site? Confirm its status
ToursFranceUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.